BL-8040 is a clinical-stage drug candidate designed to treat AML, as well as other hematological indications. The company intends to report top-line results from the trial in the
Around 120 patients at ten sites in the US will be included in the randomized, double-blind, placebo-controlled trial, which will evaluate the safety, tolerability and efficacy of KD026
The company is investing DKK1.5bn ($223m) in this new facility, which is designed to produce active pharmaceutical ingredients for NovoSeven and future products to treat haemophilia. With the
The orphan designation is held by the company’s European agent, Biological Consulting Europe, which is located in the UK. Advanced Inhalation Therapies chief medical officer Dr David Greenberg
Cynviloq, which is marketed as Genexol-PM in South Korea, is the company’s next-generation nanoparticle paclitaxel and it completed patient enrollment in the Tribeca registrational trial in January. Sorrento,
Amerigen believes that it is a first applicant to file an ANDA for Toviaz containing a Paragraph IV certification, under the provisions of the Hatch-Waxman Act. In the
The acquisition of this product will help the company focus beyond addiction and pain to include schizophrenia and other serious psychiatric disorders. With the acquisition of risperidone, Braeburn
Tuzistra XR is an extended-release oral suspension combination of codeine and chlorpheniramine indicated for oral use for relief of cough and symptoms associated with upper respiratory allergies or
Results from the multicenter, randomized, placebo controlled Phase III trial (MDS-005) showed that significantly more patients treated with lenalidomide achieved red-blood-cell-transfusion independence (RBC-TI) of at least 56 days
Under the deal, PeptiDream will use its peptide discovery platform system (PDPS) technology to produce macrocylic/constrained peptides against multiple targets of interest selected by Merck. Merck will have
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.